What It Is
Despite being searched and marketed as "NAD+ peptide," NAD+ (nicotinamide adenine dinucleotide) is not a peptide at all — it contains no amino-acid chain. It is a small nucleotide-derived coenzyme, built from a vitamin-B3-related nicotinamide group, adenine, and sugar-phosphate units, present in every cell in the body.[1]
It exists in oxidized (NAD+) and reduced (NADH) forms that shuttle electrons between metabolic reactions. The "peptide" label mainly reflects wellness-clinic marketing conventions that group it alongside actual peptide therapies, not any chemical similarity to one.
How It Works
NAD+/NADH cycling is central to how cells extract energy from food, feeding into glycolysis, the TCA cycle, and mitochondrial oxidative phosphorylation.[2] NAD+ is also consumed by several enzyme families with broader roles: sirtuins (metabolic regulation and stress response), PARPs (DNA-damage repair), and CD38 (immune and inflammatory signaling).
Because these pathways touch metabolism, DNA repair, and cellular aging biology, declining NAD+ levels with age have become a major research theme — though the size and clinical significance of that decline varies by tissue and is not uniform across the body.
Precursors vs. IV/Injectable NAD+
Research has followed two distinct paths. Oral NAD+ precursors — chiefly nicotinamide riboside (NR) and nicotinamide mononucleotide (NMN) — have been tested in multiple human trials and reliably raise NAD-related metabolites in blood with generally good tolerability.[6] Intravenous or injectable NAD+, the form typically marketed as "NAD IV therapy" for energy, anti-aging, or addiction recovery, has only pilot-level human data, such as a single small study measuring blood and urine NAD metabolites during a six-hour infusion.[12]
These two evidence bases should not be treated as interchangeable — a finding about oral NR does not automatically apply to an injectable clinic product.
What the Research Shows
Human trials of oral NR have shown it is bioavailable and raises NAD+ metabolites, and one randomized trial found NMN improved a measure of muscle insulin sensitivity in prediabetic women.[8] Results for symptom-level outcomes — fatigue, cognition, physical function — are mixed across studies, and a rise in a biomarker does not automatically translate into a proven clinical benefit.
Evidence for IV or injectable NAD+ addressing wellness, anti-aging, cognitive, or addiction-recovery claims is essentially absent at the level of controlled clinical trials; those specific claims currently rest on mechanistic plausibility and marketing rather than trial data.
Safety & Side Effects
- Oral NAD+ precursors have reasonable human tolerability data from clinical trials, with no major safety signals at studied doses
- Related vitamin B3 compounds, particularly nicotinic acid at high doses, are known to cause flushing, nausea, and blood-pressure effects, though this does not automatically apply to every NAD-related product
- Injectable or IV NAD+ carries the added risks of any infusion — site reactions, infusion reactions, and contamination or dosing-accuracy risk when a product is compounded rather than FDA-reviewed
- Long-term safety data for any NAD+ delivery route remain limited
Regulatory Status
There is no FDA-approved NAD+ injectable or IV drug product for wellness, anti-aging, energy, or addiction-recovery indications. NAD+ precursors like nicotinamide riboside are sold as dietary supplements, a lower regulatory bar than drug approval, and nicotinamide riboside chloride has separately been evaluated in the EU as a novel food ingredient rather than a medicine.
IV and injectable NAD+ products offered in clinics are typically compounded preparations, which the FDA explicitly does not review for safety, effectiveness, or quality before they reach patients.[10]